about
Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adultsThe renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptomsEnergetic stress: The reciprocal relationship between energy availability and the stress response.Association of CRP genetic variation and CRP level with elevated PTSD symptoms and physiological responses in a civilian population with high levels of traumaDifferential Genetic and Epigenetic Regulation of catechol-O-methyltransferase is Associated with Impaired Fear Inhibition in Posttraumatic Stress Disorder.Risk and resilience: genetic and environmental influences on development of the stress response.Substance use disorders assessed using the Kreek-McHugh-Schluger-Kellogg (KMSK) scale in an urban low-income and predominantly African American sample of primary care patients.Differential immune system DNA methylation and cytokine regulation in post-traumatic stress disorder.Hypercortisolemia and depression.Emotional learning and glutamate: translational perspectivesEmotion Dysregulation and Inflammation in African-American Women with Type 2 Diabetes.Sex dependent influence of a functional polymorphism in steroid 5-α-reductase type 2 (SRD5A2) on post-traumatic stress symptomsThe neurobiological toll of child abuse and neglect.The association between childhood trauma and lipid levels in an adult low-income, minority population.Antipsychotic drug use in 503 Chinese inpatients with schizophrenia.Dexamethasone facilitates fear extinction and safety discrimination in PTSD: A placebo-controlled, double-blind study.Relationship between Toxoplasma gondii seropositivity and acoustic startle response in an inner-city population.Inflammation in Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond.An angiotensin-converting enzyme (ACE) polymorphism may mitigate the effects of angiotensin-pathway medications on posttraumatic stress symptoms.Peptidergic mechanisms of action in the suprachiasmatic nucleus.GABA interacts with photic signaling in the suprachiasmatic nucleus to regulate circadian phase shifts.GABA(A) and GABA(B) agonists and antagonists alter the phase-shifting effects of light when microinjected into the suprachiasmatic region.Gender differences in 542 Chinese inpatients with schizophrenia.Affect, inflammation, and health in urban at-risk civiliansBicuculline Increases and Muscimol Reduces the Phase-Delaying Effects of Light and VIP/PHI/GRP in the Suprachiasmatic RegionNeuropeptide Y phase shifts circadian rhythms in vivo via a Y2 receptorAnalysis of the phase shifting effects of gastrin releasing peptide when microinjected into the suprachiasmatic regionInternational meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk lociGenome-wide association study in two populations to determine genetic variants associated with Toxoplasma gondii infection and relationship to schizophrenia riskThe differential effects of PTSD, MDD, and dissociation on CRP in trauma-exposed womenAssociation of HLA locus alleles with posttraumatic stress disorderAssociations of childhood trauma with food addiction and insulin resistance in African-American women with diabetes mellitusNausea in the peri-traumatic period is associated with prospective risk for PTSD symptom developmentEvaluating the impact of trauma and PTSD on epigenetic prediction of lifespan and neural integrity
P50
Q24649595-E731107A-B2A5-4BF8-9B92-FD92382809F4Q28268612-38497E1C-8165-457D-96C8-16A4B1C3F622Q30252080-5DA02A6D-20AE-4503-BBF6-CACEEC580B10Q30386886-902C67C0-1E40-47EB-ACDF-F57F9B5A01C9Q30429540-C153F6D6-DC3E-4C81-9959-194042CA3E7AQ30482099-36D95203-7130-4C80-A933-3C9302AC166BQ34789481-4422C747-EBD5-40E6-9F6F-054166E489F7Q35799705-3C85F5F5-415F-4383-8DC0-AB67BC166C21Q36161754-04A151D9-8547-49CB-99D3-FC37E77EE09AQ36363614-93D826B6-ED09-4FBC-A901-1079C1A5FA2DQ37140192-16DF4F21-3397-4354-A825-35CBB463CB66Q37163160-7399BD27-3884-44FE-B0B5-3BB3007ABF37Q37574667-0943085C-7962-4C9C-B411-824036473D6FQ37633535-7FD25889-E96E-47BB-BF65-07D48D7AC432Q38221208-43B5D7B9-53B9-471A-AB68-EF1A535C8F9FQ38736209-2736FB11-344C-4F17-8215-068410B380EDQ38791076-281B52ED-EE57-41CE-9674-F2FB909FD8B6Q38832608-24E087B9-34FA-47DE-8463-A5CC4E39600CQ39013181-CBD21E8F-AEDA-4EFA-830E-766F3EE5A277Q41478982-23F79CF7-82CC-4CA9-97B0-D2C8860D6A4CQ43942897-B0ADFD96-4687-45C7-96C1-0ADFBB3B33EFQ48683954-7B36AB95-4E64-486D-AA2D-B76367F11907Q51746379-253DD5E6-4772-477E-AAAE-CD363B8294F2Q57165036-82F10B45-2552-4DBA-91C5-85A3EBEAA0E5Q58492359-AB8D772D-6675-4505-A58B-F9A04A436F34Q58492360-CC9AE9F3-1A56-4167-945E-40B406A24BD4Q58492362-A6789459-2A73-4E99-8094-E42DB19A28D2Q90598095-BFA1CD55-8FB6-4B54-8316-5D04A4FE0CF1Q90899666-801DCEF2-E161-4F07-9CE5-57BA7253442DQ91890758-FE8DE15A-5E5B-4978-8A04-9DE76FCEDC84Q91924861-4425338F-E8D0-4101-B5FE-EFB0A23F1239Q92658513-B1FC80D6-A26A-4D2A-B4EA-2CC11A3C45EAQ93338115-AF195F5D-FD2A-4338-9403-EBDE736628F8Q94541243-37F316C4-5BED-44D5-BF22-97CA1C05A4F3
P50
description
researcher, ORCID id # 0000-0001-5476-5920
@en
wetenschapper
@nl
name
Charles Gillespie
@ast
Charles Gillespie
@en
Charles Gillespie
@es
Charles Gillespie
@nl
type
label
Charles Gillespie
@ast
Charles Gillespie
@en
Charles Gillespie
@es
Charles Gillespie
@nl
prefLabel
Charles Gillespie
@ast
Charles Gillespie
@en
Charles Gillespie
@es
Charles Gillespie
@nl
P106
P1153
7005285236
P31
P496
0000-0001-5476-5920